Breast cancer patients await ruling on Herceptin
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Long-awaited recommendations on which women should receive the breast cancer drug Herceptin are to be issued tomorrow.
Thousands of patients who could benefit from the treatment are hoping that the National Institute for Health and Clinical Excellence (Nice) will say all those with suitable early-stage breast cancer should be entitled to receive it on prescription.
But there are concerns that NHS trusts, which are already struggling with multimillion-pound deficits, will continue to restrict access to the drug, which costs £20,000 a year per patient. The Government says there will be no extra money to fund the Nice guidance on Herceptin and the cost must be found from existing budgets.
Dr Gill Morgan, chief executive of the NHS Confederation, said: "Without doubt, this will present a significant financial challenge to some organisations. The problem is that organisations have to plan their expenditure 18 months in advance and so when a drug is fast-tracked through the process - as this drug has been -it causes several difficulties.
"Trusts don't want to put too much money aside in case they end up in surplus with funds that could have gone to patient care but they have to make a guess because if they end up in deficit it is as bad and some other service has to be cut."
Roche, the maker of Herceptin, was granted a licence for its use in treating early-stage breast cancer by the European Medicines Agency last week.
The drug is already used in cases of advanced breast cancer but studies have shown that it can dramatically reduce the risk of the disease returning in women diagnosed at an earlier stage.
Women with early-stage disease have been forced to go to the High Court to seek the right to the treatment because NHS trusts have said the lack of a relevant licence meant they were under no obligation to provide it.
Under pressure from patients and ministers, Nice has fast-tracked assessment of the data on Herceptin for early breast cancer. More than 5,000 women a year diagnosed with early-stage, HER-2 positive breast cancer - an aggressive type - could benefit from Herceptin.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments